Taro Announces Resignation of Chief Financial Officer
Search jobs Taro Announces Resignation of Chief Financial Officer
HAWTHORNE, N.Y. (BUSINESS WIRE) Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) announced today that it has accepted the resignation of its Chief Financial Officer, Daphne Huang, effective August 6, 2021. Ms. Huang is leaving the Company in order to pursue other opportunities.
Mr. Uday Baldota, Taro’s CEO, stated, “On behalf of the Company, I want to thank Daphne for her valuable contributions including her efforts over the past year during the COVID-19 pandemic. We wish her the best in her future endeavors.”
BW Businessworld
Sun Pharma, Officials Including Dilip Shanghvi Settle Case Of Alleged Market Norms Violation With SEBI
Sebi had received two whistleblower complaints, wherein allegations were made against Sun Pharmaceutical Industries Ltd (SPIL) and its wholly-owned subsidiary Sun Pharmaceutical Laboratories Ltd (SPLL), alleging that the firms had been diverting funds through its sole distributor in India, Aditya Medisales Ltd.
Photo Credit :
Sun Pharmaceutical Industries Ltd and its senior officials, including Managing Director Dilip Shanghvi, on Thursday settled with regulator Sebi a case pertaining to alleged violation of listing obligation and disclosure requirements norms.
According to separate settlement orders, Sun Pharmaceutical paid over Rs 56.11 lakh towards settlement charges and Shanghvi paid Rs 62.35 lakh.
Aditya Medisales case: Sebi accepts settlement pleas of Sun Pharma, promoters
SECTIONS
Last Updated: Feb 11, 2021, 04:13 PM IST
Share
Synopsis
Sebi had initiated a probe against Sun Pharma, its managing director Dilip Shanghvi and its directors on the basis of two whistleblower complaints.
ET Online
Sebi had initiated a probe against Sun Pharma, its managing director Dilip Shanghvi and its directors on the basis of two whistleblower complaints.
INSIGHTS
NSE
Explore Now
MUMBAI: The Securities and Exchange Board of India (Sebi) today disposed of charges against Sun Pharmaceutical Industries, and its promoters and directors for alleged diversion of funds through its subsidiary Aditya Medisales, after all the plaintiffs in the case filed a settlement plea.
Sun Pharmaceuticals Industries and its founder and MD Dilip Singhvi have settled a case with market regulator SEBI with regard to allegations of funds diversion. Others who have settled the case inclu